cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5517/ccdc.csd.cc23yjk5
title: CCDC 1964797: Experimental Crystal Structure Determination

description: Related Article: Vladimir Y. Mikshiev, Alexander F. Pozharskii, Alexander Filarowski, Alexander S. Novikov, Alexander S. Antonov, Peter M. Tolstoy, Mikhail A. Vovk, Olesya V. Khoroshilova|2020|ChemPhysChem|21|651|doi:10.1002/cphc.201901104
DOI: 10.5517/ccdc.csd.cc23yjl6
title: CCDC 1964798: Experimental Crystal Structure Determination

description: Related Article: Vladimir Y. Mikshiev, Alexander F. Pozharskii, Alexander Filarowski, Alexander S. Novikov, Alexander S. Antonov, Peter M. Tolstoy, Mikhail A. Vovk, Olesya V. Khoroshilova|2020|ChemPhysChem|21|651|doi:10.1002/cphc.201901104
DOI: 10.5517/ccdc.csd.cc23yjm7
title: CCDC 1964799: Experimental Crystal Structure Determination

description: Related Article: Vladimir Y. Mikshiev, Alexander F. Pozharskii, Alexander Filarowski, Alexander S. Novikov, Alexander S. Antonov, Peter M. Tolstoy, Mikhail A. Vovk, Olesya V. Khoroshilova|2020|ChemPhysChem|21|651|doi:10.1002/cphc.201901104
DOI: 10.5517/ccdc.csd.cc24l755
title: CCDC 1983726: Experimental Crystal Structure Determination

description: Related Article: Chunhua Tony Hu|2020|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc24l7hh
title: CCDC 1983736: Experimental Crystal Structure Determination

description: Related Article: Thomas Fellowes, Jonathan M. White|2020|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc24l913
title: CCDC 1983784: Experimental Crystal Structure Determination

description: Related Article: Carsten Präsang, Armin Berndt, Gertraud Geiseler, Werner Massa|2020|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc21y89l
title: CCDC 1904959: Experimental Crystal Structure Determination

description: Related Article: Lun Zhang, Pei‐Pei Yang, Ling‐Fei Li, Yi‐Ye Hu, Yu Gao, Jin Tao|2020|Appl.Organomet.Chem.|34|e5331|doi:10.1002/aoc.5331
DOI: 10.5517/ccdc.csd.cc21y8bm
title: CCDC 1904960: Experimental Crystal Structure Determination

description: Related Article: Lun Zhang, Pei‐Pei Yang, Ling‐Fei Li, Yi‐Ye Hu, Yu Gao, Jin Tao|2020|Appl.Organomet.Chem.|34|e5331|doi:10.1002/aoc.5331
DOI: 10.5517/ccdc.csd.cc21y8cn
title: CCDC 1904961: Experimental Crystal Structure Determination

description: Related Article: Lun Zhang, Pei‐Pei Yang, Ling‐Fei Li, Yi‐Ye Hu, Yu Gao, Jin Tao|2020|Appl.Organomet.Chem.|34|e5331|doi:10.1002/aoc.5331
DOI: 10.5517/ccdc.csd.cc21y8dp
title: CCDC 1904962: Experimental Crystal Structure Determination

description: Related Article: Lun Zhang, Pei‐Pei Yang, Ling‐Fei Li, Yi‐Ye Hu, Yu Gao, Jin Tao|2020|Appl.Organomet.Chem.|34|e5331|doi:10.1002/aoc.5331
DOI: 10.5517/ccdc.csd.cc23kp5k
title: CCDC 1953408: Experimental Crystal Structure Determination

description: Related Article: Ting Hei Matthew Wong, Xingguang Li, Dengke Ma, Jianwei Sun|2020|Org.Lett.|22|1951|doi:10.1021/acs.orglett.0c00300
DOI: 10.5517/ccdc.csd.cc23lcnr
title: CCDC 1954074: Experimental Crystal Structure Determination

description: Related Article: Renzhong Wang, Yanfei Liu, Guoru Shi, Jie Zhou, Jiayuan Li, Li Li, Jiqiao Yuan, Xuyu Li, Dequan Yu|2020|Bioorg.Chem.|98|103697|doi:10.1016/j.bioorg.2020.103697
DOI: 10.5517/ccdc.csd.cc23lcps
title: CCDC 1954075: Experimental Crystal Structure Determination

description: Related Article: Renzhong Wang, Yanfei Liu, Guoru Shi, Jie Zhou, Jiayuan Li, Li Li, Jiqiao Yuan, Xuyu Li, Dequan Yu|2020|Bioorg.Chem.|98|103697|doi:10.1016/j.bioorg.2020.103697
DOI: 10.5517/ccdc.csd.cc23lcqt
title: CCDC 1954076: Experimental Crystal Structure Determination

description: Related Article: Renzhong Wang, Yanfei Liu, Guoru Shi, Jie Zhou, Jiayuan Li, Li Li, Jiqiao Yuan, Xuyu Li, Dequan Yu|2020|Bioorg.Chem.|98|103697|doi:10.1016/j.bioorg.2020.103697
DOI: 10.5517/ccdc.csd.cc23lpp3
title: CCDC 1954385: Experimental Crystal Structure Determination

description: Related Article: Joan Soldevila-Sanmartín, Miguel Guerrero, Duane Choquesillo-Lazarte, José Giner Planas, Josefina Pons|2020|Inorg.Chim.Acta|506|119549|doi:10.1016/j.ica.2020.119549
DOI: 10.5517/ccdc.csd.cc23lpq4
title: CCDC 1954386: Experimental Crystal Structure Determination

description: Related Article: Joan Soldevila-Sanmartín, Miguel Guerrero, Duane Choquesillo-Lazarte, José Giner Planas, Josefina Pons|2020|Inorg.Chim.Acta|506|119549|doi:10.1016/j.ica.2020.119549
DOI: 10.5517/ccdc.csd.cc23yjn8
title: CCDC 1964800: Experimental Crystal Structure Determination

description: Related Article: Vladimir Y. Mikshiev, Alexander F. Pozharskii, Alexander Filarowski, Alexander S. Novikov, Alexander S. Antonov, Peter M. Tolstoy, Mikhail A. Vovk, Olesya V. Khoroshilova|2020|ChemPhysChem|21|651|doi:10.1002/cphc.201901104
DOI: 10.5517/ccdc.csd.cc23yjp9
title: CCDC 1964801: Experimental Crystal Structure Determination

description: Related Article: Vladimir Y. Mikshiev, Alexander F. Pozharskii, Alexander Filarowski, Alexander S. Novikov, Alexander S. Antonov, Peter M. Tolstoy, Mikhail A. Vovk, Olesya V. Khoroshilova|2020|ChemPhysChem|21|651|doi:10.1002/cphc.201901104
DOI: 10.5517/ccdc.csd.cc23yjqb
title: CCDC 1964802: Experimental Crystal Structure Determination

description: Related Article: Vladimir Y. Mikshiev, Alexander F. Pozharskii, Alexander Filarowski, Alexander S. Novikov, Alexander S. Antonov, Peter M. Tolstoy, Mikhail A. Vovk, Olesya V. Khoroshilova|2020|ChemPhysChem|21|651|doi:10.1002/cphc.201901104
DOI: 10.5517/ccdc.csd.cc23yjrc
title: CCDC 1964803: Experimental Crystal Structure Determination

description: Related Article: Vladimir Y. Mikshiev, Alexander F. Pozharskii, Alexander Filarowski, Alexander S. Novikov, Alexander S. Antonov, Peter M. Tolstoy, Mikhail A. Vovk, Olesya V. Khoroshilova|2020|ChemPhysChem|21|651|doi:10.1002/cphc.201901104
DOI: 10.5517/ccdc.csd.cc23yjsd
title: CCDC 1964804: Experimental Crystal Structure Determination

description: Related Article: Vladimir Y. Mikshiev, Alexander F. Pozharskii, Alexander Filarowski, Alexander S. Novikov, Alexander S. Antonov, Peter M. Tolstoy, Mikhail A. Vovk, Olesya V. Khoroshilova|2020|ChemPhysChem|21|651|doi:10.1002/cphc.201901104
DOI: 10.5517/ccdc.csd.cc23j7yv
title: CCDC 1952037: Experimental Crystal Structure Determination

description: Related Article: James D. Cope,  Henry U. Valle,  Ruby S. Hall,  Kathleen M. Riley,  Ekta Goel,  Saborni Biswas,  Michael P. Hendrich,  David O. Wipf,  Sean L. Stokes,  Joseph Emerson|2020|Eur.J.Inorg.Chem.|2020|1278|doi:10.1002/ejic.201901269
DOI: 10.5517/ccdc.csd.cc23lpr5
title: CCDC 1954387: Experimental Crystal Structure Determination

description: Related Article: Joan Soldevila-Sanmartín, Miguel Guerrero, Duane Choquesillo-Lazarte, José Giner Planas, Josefina Pons|2020|Inorg.Chim.Acta|506|119549|doi:10.1016/j.ica.2020.119549
DOI: 10.5517/ccdc.csd.cc23lps6
title: CCDC 1954388: Experimental Crystal Structure Determination

description: Related Article: Joan Soldevila-Sanmartín, Miguel Guerrero, Duane Choquesillo-Lazarte, José Giner Planas, Josefina Pons|2020|Inorg.Chim.Acta|506|119549|doi:10.1016/j.ica.2020.119549
DOI: 10.5517/ccdc.csd.cc23lpt7
title: CCDC 1954389: Experimental Crystal Structure Determination

description: Related Article: Joan Soldevila-Sanmartín, Miguel Guerrero, Duane Choquesillo-Lazarte, José Giner Planas, Josefina Pons|2020|Inorg.Chim.Acta|506|119549|doi:10.1016/j.ica.2020.119549
DOI: 10.5517/ccdc.csd.cc23trzp
title: CCDC 1961183: Experimental Crystal Structure Determination

description: Related Article: Matthew C. Davis, Thomas J. Groshens, Gregory H. Imler|2020|Tetrahedron Lett.|61|151776|doi:10.1016/j.tetlet.2020.151776
DOI: 10.5517/ccdc.csd.cc23w0pq
title: CCDC 1962383: Experimental Crystal Structure Determination

description: Related Article: Matthew C. Davis, Thomas J. Groshens, Gregory H. Imler|2020|Tetrahedron Lett.|61|151776|doi:10.1016/j.tetlet.2020.151776
DOI: 10.5517/ccdc.csd.cc23w65d
title: CCDC 1962553: Experimental Crystal Structure Determination

description: Related Article: Matthew C. Davis, Thomas J. Groshens, Gregory H. Imler|2020|Tetrahedron Lett.|61|151776|doi:10.1016/j.tetlet.2020.151776
DOI: 10.5517/ccdc.csd.cc23yjtf
title: CCDC 1964805: Experimental Crystal Structure Determination

description: Related Article: Vladimir Y. Mikshiev, Alexander F. Pozharskii, Alexander Filarowski, Alexander S. Novikov, Alexander S. Antonov, Peter M. Tolstoy, Mikhail A. Vovk, Olesya V. Khoroshilova|2020|ChemPhysChem|21|651|doi:10.1002/cphc.201901104
DOI: 10.5517/ccdc.csd.cc23yjvg
title: CCDC 1964806: Experimental Crystal Structure Determination

description: Related Article: Vladimir Y. Mikshiev, Alexander F. Pozharskii, Alexander Filarowski, Alexander S. Novikov, Alexander S. Antonov, Peter M. Tolstoy, Mikhail A. Vovk, Olesya V. Khoroshilova|2020|ChemPhysChem|21|651|doi:10.1002/cphc.201901104
DOI: 10.5517/ccdc.csd.cc2408wb
title: CCDC 1966481: Experimental Crystal Structure Determination

description: Related Article: Matthew C. Davis, Thomas J. Groshens, Gregory H. Imler|2020|Tetrahedron Lett.|61|151776|doi:10.1016/j.tetlet.2020.151776
DOI: 10.5517/ccdc.csd.cc21z87k
title: CCDC 1905918: Experimental Crystal Structure Determination

description: Related Article: Zeng-Chuan Hao, Sheng-Chun Wang, Ying-Jie Yang, Guang-Hua Cui|2020|Polyhedron|181|114466|doi:10.1016/j.poly.2020.114466
DOI: 10.5517/ccdc.csd.cc23lpv8
title: CCDC 1954390: Experimental Crystal Structure Determination

description: Related Article: Joan Soldevila-Sanmartín, Miguel Guerrero, Duane Choquesillo-Lazarte, José Giner Planas, Josefina Pons|2020|Inorg.Chim.Acta|506|119549|doi:10.1016/j.ica.2020.119549
DOI: 10.5517/ccdc.csd.cc23xq92
title: CCDC 1964014: Experimental Crystal Structure Determination

description: Related Article: Biswarup Chakraborty, Ivy Ghosh, Rahul Dev Jana, Tapan Kanti Paine|2020|Dalton Trans.|49|3463|doi:10.1039/C9DT04438H
DOI: 10.5281/zenodo.15208699
title: India Pharmaceutical Market 2024 To 2033

description: India Pharmaceutical Market Size, Trends and Insights By Therapeutic Category (Anti-Infectives, Cardiovascular, Gastrointestinal, Anti-Diabetic, Respiratory, Dermatologicals, Musculo-Skeletal System, Nervous System, Others), By Drug Type (Prescription Drug, OTC Drug), By Distribution Channel (Online, Offline), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033.

Reports Description

India Pharmaceutical Market was valued at USD 59.63 Billion in 2022 and is expected to reach USD 129.49 Billion by 2032, at a CAGR of 9.48% during the forecast period 2023 – 2032.

Indian Pharmaceutical sector is a global giant in all medical supplies. The Indian pharmaceutical industry holds a significant place in the global economy. It ranks third in volume and fourteenth in value worldwide. India accounts for 60% of global vaccine production making it the largest vaccine producer in the world.

Indian Pharmaceutical industry is composed of generic drugs, OTC medicines, bulk drugs, vaccines, contract research & manufacturing, biosimilar and biologics. India exports pharmaceuticals products and drugs to around 200 countries and territories in the world, including highly regulated markets such as the USA, UK, European Union, Canada etc.

For more information, DOWNLOAD FREE SAMPLE Now at https://www.custommarketinsights.com/request-for-free-sample/?reportid=42311
DOI: 10.5281/zenodo.15208700
title: India Pharmaceutical Market 2024 To 2033

description: India Pharmaceutical Market Size, Trends and Insights By Therapeutic Category (Anti-Infectives, Cardiovascular, Gastrointestinal, Anti-Diabetic, Respiratory, Dermatologicals, Musculo-Skeletal System, Nervous System, Others), By Drug Type (Prescription Drug, OTC Drug), By Distribution Channel (Online, Offline), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033.

Reports Description

India Pharmaceutical Market was valued at USD 59.63 Billion in 2022 and is expected to reach USD 129.49 Billion by 2032, at a CAGR of 9.48% during the forecast period 2023 – 2032.

Indian Pharmaceutical sector is a global giant in all medical supplies. The Indian pharmaceutical industry holds a significant place in the global economy. It ranks third in volume and fourteenth in value worldwide. India accounts for 60% of global vaccine production making it the largest vaccine producer in the world.

Indian Pharmaceutical industry is composed of generic drugs, OTC medicines, bulk drugs, vaccines, contract research & manufacturing, biosimilar and biologics. India exports pharmaceuticals products and drugs to around 200 countries and territories in the world, including highly regulated markets such as the USA, UK, European Union, Canada etc.

For more information, DOWNLOAD FREE SAMPLE Now at https://www.custommarketinsights.com/request-for-free-sample/?reportid=42311
DOI: 10.6084/m9.figshare.16800190
title: Additional file 5 of Breed-specific reference sequence optimized mapping accuracy of NGS analyses for pigs

description: Additional file 5: Table S5. Polymorphic loci among the three kinds of reference sequences.
DOI: 10.6084/m9.figshare.11557311
title: MOESM6 of Metabolomic analyses reveal substances that contribute to the increased freezing tolerance of alfalfa (Medicago sativa L.) after continuous water deficit

description: Additional file 6. The raw data for all the metabolites detected in the seven comparisons.
DOI: 10.6084/m9.figshare.16800190.v1
title: Additional file 5 of Breed-specific reference sequence optimized mapping accuracy of NGS analyses for pigs

description: Additional file 5: Table S5. Polymorphic loci among the three kinds of reference sequences.
DOI: 10.6084/m9.figshare.11557311.v1
title: MOESM6 of Metabolomic analyses reveal substances that contribute to the increased freezing tolerance of alfalfa (Medicago sativa L.) after continuous water deficit

description: Additional file 6. The raw data for all the metabolites detected in the seven comparisons.
DOI: 10.6084/m9.figshare.16800202
title: Additional file 2 of Defining matrix Gla protein expression in the Dunkin-Hartley guinea pig model of spontaneous osteoarthritis

description: Additional file 2.
DOI: 10.6084/m9.figshare.16800202.v1
title: Additional file 2 of Defining matrix Gla protein expression in the Dunkin-Hartley guinea pig model of spontaneous osteoarthritis

description: Additional file 2.
DOI: 10.6084/m9.figshare.16800211
title: Additional file 1 of Impact of rising temperatures on the biomass of humid old-growth forests of the world

description: Additional file 1. Sensitivity of results relative parameters, parameter bounds and data selection criteria.
DOI: 10.6084/m9.figshare.16800211.v1
title: Additional file 1 of Impact of rising temperatures on the biomass of humid old-growth forests of the world

description: Additional file 1. Sensitivity of results relative parameters, parameter bounds and data selection criteria.
DOI: 10.6084/m9.figshare.6838748
title: Additional file 15: of Genome-wide analysis of genes encoding core components of the ubiquitin system in soybean (Glycine max) reveals a potential role for ubiquitination in host immunity against soybean cyst nematode

description: Table S4. Summary of the number of soybean UBS genes underwent different types of duplications. (XLSX 9 kb)
DOI: 10.6084/m9.figshare.6838748.v1
title: Additional file 15: of Genome-wide analysis of genes encoding core components of the ubiquitin system in soybean (Glycine max) reveals a potential role for ubiquitination in host immunity against soybean cyst nematode

description: Table S4. Summary of the number of soybean UBS genes underwent different types of duplications. (XLSX 9 kb)
DOI: 10.6084/m9.figshare.14178785
title: A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes

description: Hypertension commonly co-exists with diabetes mellitus (DM), and both are closely related to adverse health outcomes. The activation of aldosterone and mineralocorticoid receptor (MR) may play important roles in this process. Therefore, we aim to evaluate the efficacy of MR antagonists on cardiovascular risk factors, including blood pressure (BP), glucose, lipids, renal function, fibrosis and inflammatory and its safety in patients with both hypertension and DM. We searched PubMed, Embase, Web of Science and Cochrane databases for clinical trials published until December 31, 2019. Studies comparing the effect of spironolactone to placebo in patients with hypertension and DM were included. Mean difference with 95% confidence intervals was used to report outcomes. Eleven randomised placebo-controlled trials with 640 participants were finally included with mean follow-up of 5 months. Compared to placebo, spironolactone significantly reduced office systolic (–6.57, 95%CI: −9.21, −3.93) and diastolic BP (–2.63, 95%CI: −4.25, −1.02) as well as ambulatory BP; increased glycosylated haemoglobin by 0.3 but no clear effect on fasting glucose. Spironolactone induced a significantly reduction of urinary albumin but increased serum creatinine (7.60, 95%CI: 4.94, 10.27) and decreased glomerular filtration rate (–4.28, 95%CI: −6.38, −2.18). Markers of fibrosis and inflammation, including NIIINP, PICP, hs-CRP and TNF-α were also decreased after spironolactone therapy. For lipid metabolism, there was no significant difference between groups. Spironolactone mildly increased serum potassium (0.30, 95%CI: 0.23, 0.37). 2.5% subjects treated with spironolactone experienced mild to moderate hyperkalaemia and received medication or dietary advice and another 1.6% developed severe hyperkalaemia and withdrawn from the studies. Spironolactone reduced BP and urinary albumin, improve fibrosis and inflammation, whereas slightly increases the glycosylated haemoglobin and serum creatinine in patients with hypertension and diabetes. Long-term RCTs to assess the effects of spironolactone on cardiovascular events in this population are warranted.
DOI: 10.6084/m9.figshare.14178785.v1
title: A systematic review and meta-analysis of effects of spironolactone on blood pressure, glucose, lipids, renal function, fibrosis and inflammation in patients with hypertension and diabetes

description: Hypertension commonly co-exists with diabetes mellitus (DM), and both are closely related to adverse health outcomes. The activation of aldosterone and mineralocorticoid receptor (MR) may play important roles in this process. Therefore, we aim to evaluate the efficacy of MR antagonists on cardiovascular risk factors, including blood pressure (BP), glucose, lipids, renal function, fibrosis and inflammatory and its safety in patients with both hypertension and DM. We searched PubMed, Embase, Web of Science and Cochrane databases for clinical trials published until December 31, 2019. Studies comparing the effect of spironolactone to placebo in patients with hypertension and DM were included. Mean difference with 95% confidence intervals was used to report outcomes. Eleven randomised placebo-controlled trials with 640 participants were finally included with mean follow-up of 5 months. Compared to placebo, spironolactone significantly reduced office systolic (–6.57, 95%CI: −9.21, −3.93) and diastolic BP (–2.63, 95%CI: −4.25, −1.02) as well as ambulatory BP; increased glycosylated haemoglobin by 0.3 but no clear effect on fasting glucose. Spironolactone induced a significantly reduction of urinary albumin but increased serum creatinine (7.60, 95%CI: 4.94, 10.27) and decreased glomerular filtration rate (–4.28, 95%CI: −6.38, −2.18). Markers of fibrosis and inflammation, including NIIINP, PICP, hs-CRP and TNF-α were also decreased after spironolactone therapy. For lipid metabolism, there was no significant difference between groups. Spironolactone mildly increased serum potassium (0.30, 95%CI: 0.23, 0.37). 2.5% subjects treated with spironolactone experienced mild to moderate hyperkalaemia and received medication or dietary advice and another 1.6% developed severe hyperkalaemia and withdrawn from the studies. Spironolactone reduced BP and urinary albumin, improve fibrosis and inflammation, whereas slightly increases the glycosylated haemoglobin and serum creatinine in patients with hypertension and diabetes. Long-term RCTs to assess the effects of spironolactone on cardiovascular events in this population are warranted.
DOI: 10.6084/m9.figshare.11557350
title: MOESM2 of Genome wide identification and functional characterization of strawberry pectin methylesterases related to fruit softening

description: Additional file 2: Table S1. Primers used for this study. Table S2. Pectin methylesterases were identified in Arabidopsis thaliana, Fragaria vesca, Malus domestica, Pyrus bretschneideri, Prunus mume, Prunus persica and Rosa chinensis. Table S3. Conserved domains were predicted by CDD. Table S4. Gene duplication modes of PME genes in Arabidopsis thaliana, Fragaria vesca, Malus domestica, Pyrus bretschneideri, Prunus mume, Prunus persica and Rosa chinensis. Table S5. Cis-elements were predicted by PlantCARE in promoter sequences of FvPME genes.
DOI: 10.6084/m9.figshare.11557350.v1
title: MOESM2 of Genome wide identification and functional characterization of strawberry pectin methylesterases related to fruit softening

description: Additional file 2: Table S1. Primers used for this study. Table S2. Pectin methylesterases were identified in Arabidopsis thaliana, Fragaria vesca, Malus domestica, Pyrus bretschneideri, Prunus mume, Prunus persica and Rosa chinensis. Table S3. Conserved domains were predicted by CDD. Table S4. Gene duplication modes of PME genes in Arabidopsis thaliana, Fragaria vesca, Malus domestica, Pyrus bretschneideri, Prunus mume, Prunus persica and Rosa chinensis. Table S5. Cis-elements were predicted by PlantCARE in promoter sequences of FvPME genes.
DOI: 10.6084/m9.figshare.11557386
title: Additional file 1: of Establishment of long-term serum-free culture for lacrimal gland stem cells aiming at lacrimal gland repair

description: Table S1. The list of primary antibodies. All the primary antibodies used in this study. Table S2. The list of fluorescent secondary antibodies. All the flourescent secondary antibodies used in this study (XLS 33 kb)
DOI: 10.6084/m9.figshare.11557386.v1
title: Additional file 1: of Establishment of long-term serum-free culture for lacrimal gland stem cells aiming at lacrimal gland repair

description: Table S1. The list of primary antibodies. All the primary antibodies used in this study. Table S2. The list of fluorescent secondary antibodies. All the flourescent secondary antibodies used in this study (XLS 33 kb)
DOI: 10.6084/m9.figshare.6838796
title: Additional file 18: of Genome-wide analysis of genes encoding core components of the ubiquitin system in soybean (Glycine max) reveals a potential role for ubiquitination in host immunity against soybean cyst nematode

description: Table S5. Expression pattern of UBS genes as revealed by RNA-seq analysis. (XLSX 213 kb)
DOI: 10.6084/m9.figshare.6838796.v1
title: Additional file 18: of Genome-wide analysis of genes encoding core components of the ubiquitin system in soybean (Glycine max) reveals a potential role for ubiquitination in host immunity against soybean cyst nematode

description: Table S5. Expression pattern of UBS genes as revealed by RNA-seq analysis. (XLSX 213 kb)
DOI: 10.6084/m9.figshare.11557389
title: Additional file 2: of Establishment of long-term serum-free culture for lacrimal gland stem cells aiming at lacrimal gland repair

description: Table S3. Sequences of primers. All the sequences of primers used in this study (XLS 27 kb)
DOI: 10.6084/m9.figshare.11557389.v1
title: Additional file 2: of Establishment of long-term serum-free culture for lacrimal gland stem cells aiming at lacrimal gland repair

description: Table S3. Sequences of primers. All the sequences of primers used in this study (XLS 27 kb)
DOI: 10.6084/m9.figshare.11557398
title: Additional file 3: of Establishment of long-term serum-free culture for lacrimal gland stem cells aiming at lacrimal gland repair

description: Table S4. Differential expressed gene list of LGSCs cultured 7 days and 14 days. All the genes expressed differentially between day 7 LGSCs and day 14 LGSCs (XLS 44 kb)